Could QALYs help in assessing high-priced cancer treatments?

Managed Care

Volumn 22, Issue 12, 2013, Pages 32-37

  McCain, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; HUMAN; METHODOLOGY; NEOPLASM; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84893950263     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (11)

1. Bach PB, Saltz LB, Wittes RE. In cancer care, cost matters. New York Times. October 14, 2012.
2. Emanuel EJ. A plan to fix cancer care. New York Times. March 23, 2013.
3. Nadler E, Eckert B, Neumann PJ. Do oncologists believenew cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
4. Neumann PJ. What next for QALYs? JAMA. 2011;305(17):1806-1807.
5. Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Aff (Millwood). 2009;28(5):1366-1371.
6. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood). 2010a;29(1):196-202.
7. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010b;363(16):1495-1497.
8. Round J. Is a QALY still a QALY at the end of life? J Health Econ. 2012;31(3):521-527.
9. Seabury SA, Goldman DP, Maclean JR, Penrod JR, Lakdawalla DN. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood). 2012;31(4):691-699.
10. Ubel PA, Berry SR, Nadler E, Bell CM, Kozminski MA, Palmer JA, Evans WK, Strevel EL, Neumann PJ. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
11. Woodward RM, Menzin J, Neumann PJ. Quality-adjusted life years in cancer: pros, cons, and alternatives. Eur J Cancer Care (Engl). 2013;22(1):12-19.